[Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain. A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up. Radiation therapy was performed, by using a total focal dose of 65 Gy in 2 steps or a single dose of 1.25 Gy twice daily every 4-6 hours. The patients received lomustin in a single oral dose of 160-200 mg at each of 2 stages of a hyperfractionated course of radiation therapy. The interval between two successive administrations was 5 weeks. Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.
A S
AS
Balkanov
M F
MF
Makarenko
P Iu
PIu
Poliakov
I A
IA
Kachkov
D000328:Adult; D000367:Age Factors; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003907:Dexamethasone / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D008130:Lomustine; D003907:Dexamethasone